Thyme Klinger News Today

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) insider Shannon Thyme Klinger sold 1,296 shares of the business’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $162.47, for a total transaction of $210,561.12. Following the transaction, the insider now owns 10,623 shares in the company, valued at […]

Moderna Reviews its Environmental, Social and Governance Progress and Ambitions at Second ESG Investor Event The Companys ESG strategy demonstrates its efforts to advance global health and...

Government officials, lawmakers and health policy experts said the U.S. is prepared for the next pandemic but also detailed health care challenges.

Read on to learn more about Moderna leaders and executives working together to revolutionize what we know about medicine.

Moderna, Inc. (NASDAQ:MRNA – Get Rating) insider Shannon Thyme Klinger sold 110 shares of the company’s stock in a transaction that occurred on Friday, June 2nd. The stock was sold at an average price of $130.32, for a total value of $14,335.20. Following the sale, the insider now directly owns 5,942 shares of the company’s […]

Additionally, CureVac has expanded its counterclaim against Pfizer and BioNTech to allege infringement of nine U.S. patents by the manufacturing and distribution of Comirnaty.

Moderna has led the development of COVID-19 vaccine through mRNA technology. Learn about Moderna Inc. leaders and executives here.

Read on to learn more about Moderna leaders and executives working together to revolutionize what we know about medicine.

Moderna yesterday filed patent infringement lawsuits against Pfizer and BioNTech, alleging the two companies copied Moderna’s patented mRNA ...

Pfizer shares slumped lower Friday after rival vaccine maker Moderna said it would sue the pharma giant, as well as its German partner BioNTech, for allegedly copying its messenger-RNA technologies.